Akili Reports FDA Clearance Of EndeavorOTC (AKL-T01) As An Over-the-counter Treatment For Adults With Attention-deficit/Hyperactivity Disorder
Akili Reports FDA Clearance Of EndeavorOTC (AKL-T01) As An Over-the-counter Treatment For Adults With Attention-deficit/Hyperactivity Disorder
Akili宣佈其EndeavorOTC (AKL-T01)獲得FDA批准，作爲一種針對成人注意力缺陷/多動障礙的非處方治療藥物。
Akili Reports FDA Clearance Of EndeavorOTC (AKL-T01) As An Over-the-counter Treatment For Adults With Attention-deficit/Hyperactivity Disorder
Akili宣佈其EndeavorOTC (AKL-T01)獲得FDA批准，作爲一種針對成人注意力缺陷/多動障礙的非處方治療藥物。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。